The definitive agreement encompasses a suite of established diagnostic products, including the Prequel, Foresight, SneakPeek, and FirstGene tests. For Myriad, the divestiture is the outcome of a comprehensive strategic review aimed at bolstering profitability and strengthening the company's balance sheet. By shedding this segment, the firm anticipates a more streamlined path toward long-term revenue growth.

Labcorp views the acquisition as a tactical move to scale its specialty testing portfolio. The company projects the integration will generate approximately $160 million in additional revenue, with expectations for a modest lift to earnings within the first year of operation. The transaction price includes the base cash payment plus the value of existing inventory, with both parties targeting an exit from the prenatal space for Myriad and a consolidation of diagnostic assets for Labcorp.